What is Progenesis?
Founded in 2015 and headquartered in La Jolla, California, Progenesis specializes in preimplantation genetic testing (PGT) and associated assessments crucial for In Vitro Fertilization (IVF) treatments. Their comprehensive service portfolio includes PGT-A (Previda), PGT-M/SR (Previda-DX), mitochondrial DNA assessments (MitoSure), and accessible genetic counseling via their online platform, Revela. By leveraging advanced technology and a team of expert geneticists, Progenesis empowers individuals and couples with detailed insights to support their family planning objectives, solidifying its role as a leader in personalized reproductive genetic services.
How much funding has Progenesis raised?
Progenesis has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Progenesis?
The substantial backing indicated by the $150K suggests Progenesis is in a robust phase of its corporate lifecycle, likely focused on scaling operations and expanding its market reach. This large-scale, late-stage funding, coupled with the recent strategic investment, positions the company for accelerated innovation in genetic diagnostics and broader adoption of its specialized IVF-related services. Future developments may include further technological advancements, strategic partnerships, and enhanced service offerings to meet the evolving demands of assisted reproductive technologies.
See full Progenesis company page
